奥拉帕利维持治疗BRCA突变铂敏感复发性卵巢癌的真实世界数据及进展后结局
这项非干预性回顾性研究收集了13个中心234例BRCA突变铂敏感复发性卵巢癌患者,按说明书接受奥拉帕利维持治疗。中位无进展生存期为14.7个月(95%CI 12.6-18),中位总生存期未达到,最常见3-4级毒性为贫血(6%)。进展后接受进一步治疗可评估的66例患者中,无铂间期超过12个月、6-12个月和小于6个月者的客观缓解率分别为22.2%、11.1%和9.5%。
要点
- 中位无进展生存期14.7个月,基线血清CA125正常、末次铂类治疗后完全缓解及在二线铂类后使用奥拉帕利者无进展生存期更长。
- 3-4级贫血发生率为6%,因毒性停药和减量分别占4.7%和20.9%。
- 进展后化疗客观缓解率随无铂间期缩短而降低,提示可能存在交叉耐药。
核心结论
- 奥拉帕利在真实世界环境中有效且安全,进展后治疗数据似乎提示与化疗存在交叉耐药,需在更大规模研究中确认。
研究设计与样本
- 非干预性回顾性研究,收集13个中心按说明书接受奥拉帕利治疗的患者,共分析234例,所有患者均为BRCA突变且多数为胚系突变。
主要发现
- 约50%的患者在3线或以上铂类化疗后接受奥拉帕利,达到影像学完全或部分缓解,12.4%为疾病稳定患者也被纳入。
- 中位无进展生存期为14.7个月(95%CI 12.6-18),基线血清CA125正常、末次铂类治疗后完全缓解及在二线铂类后接受奥拉帕利者无进展生存期有统计学显著延长。
- 中位总生存期未达到。
- 最常见的3-4级毒性为贫血(6%),因毒性停药11例(4.7%),减量49例(20.9%)。
- 进展后接受进一步治疗且可评估疗效的66例患者中,无铂间期超过12个月、6-12个月和小于6个月者的客观缓解率分别为22.2%、11.1%和9.5%。
局限性
- 原文指出进展后治疗数据需在更大规模研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Olaparib is approved as maintenance therapy in patients with BRCA mutated platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based therapy. Few data are available regarding the use out of the registration trials and on response to further treatments after progression. MATERIALS AD METHODS: In this non interventional, retrospective study, patients treated with olaparib in 13 centers, according to the label, have been collected and analyzed. Primary objectives of the study are to describe effectiveness and safety of olaparib in a real world setting with a focus on post progression treatments and response. RESULTS: 234 patients were analyzed. All patients were BRCA mutated and most of them had germline mutations. Around 50% of the patients received olaparib after 3 or more lines of platinum based chemotherapy achieving a radiologic complete (CR) or partial response. 12.4% patients with stable disease were also included. Median PFS was 14.7 months (95% CI:12.6-18), with statistically longer PFS in patients with normal serum Ca125 at baseline, a CR after last platinum based therapy and that received olaparib after second platinum based therapy. Median OS was not reached. Most frequent G3-G4 toxicity was anaemia (6%) with dose discontinuation and dose reduction in 11 (4.7%) and 49 (20.9%) of cases, respectively. Among 66 patients receiving further treatment after olaparib progression and evaluable for response, ORR was 22.2, 11.1% and 9.5% in patients with Platinum Free interval (PFI) of more than 12 months, between 6 and 12 months and less than 6 months, respectively. CONCLUSIONS: Olaparib is effective and safe in real world setting. Data on post-progression treatments seem to suggest cross resistance with chemotherapy and need to be confirmed in larger studies because of the potential importance in clinical practice decisions.
引用
- Cecere SC, Giannone G, Salutari V, et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. Gynecol Oncol. 2019. PMID: 31699415. doi:10.1016/j.ygyno.2019.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。